a2g - you are searching for reasons to be negative.
The key piece of news on the process enhancements was that they have ELIMINATED a reagent transfer step. This is the significant piece of news and is separate from any discussion of pipettes.
As for your claim that the test does not stack up commercially because there are pipettes involved - from a handling steps perspective it possibly does not stack up against the automated version of HC2 that is used by the very biggest labs - but the vast majority of labs do not run an automated version of HC2 as they can't justify it given their volumes.
My understanding is that most elements of the PapType test are well suited to automation - but it will cost approx $3 million to go down the automation path and GBI is focussed on getting the product into the market - as most labs won't be focussed on automation in this product area in the near term - before worrying about automation down the track.
GBI Price at posting:
47.0¢ Sentiment: Buy Disclosure: Held
